No-moat Clinuvel CUV is suspending early-stage clinical trials evaluating afamelanotide, a synthetic drug already used in its ...

Today I’m going to think a bit about step four and beyond: how an investor might find potential investments that are aligned ...

With the cost of education increasing and federal re-election campaigns fired up, find out what new changes to HECS may mean ...

Munger wanted to make a point about what it takes to be successful at investing or anything else in life. He said, “the first ...

Signs of improvement in continued improvement in core business.

Our Fair Value estimate for MinRes is $64 per share or almost 70% higher than current share price levels of around $38. Mark ...

Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian ...

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, ...

New research reveals undiagnosed cognitive decline can cost retirees tens of thousands of dollars through bad investments or ...

Tesla shares rose roughly 28% this past week on news that Donald Trump was elected to become the next US president. The ...

Nonetheless, with ACCC approval, we raise our fair value estimate for no-moat Sigma by 99% to AUD 1.55 per share with the ...

This week's chart of the week looks at the minimal impact on markets that party has, and instead focuses on another measure ...